Search results
AstraZeneca in China. At AstraZeneca, we turn ideas into life-changing medicines. Working here in China means having the freedom to make the impossible a reality. Collaborating within a high-performance culture, you’ll enjoy a fast-paced career that will push your skillset.
Jun 18, 2023 · AstraZeneca has drawn up plans to break out its China business and list it separately in Hong Kong as a way to shelter the company against mounting geopolitical tensions.
May 21, 2024 · AstraZeneca is building a separate Chinese supply chain to try to circumvent increased US-China tensions, as chief executive Pascal Soriot said Chinese drug sales and innovation would help the...
Jun 26, 2024 · AstraZeneca’s Tagrisso (osimertinib) with the addition of pemetrexed and platinum-based chemotherapy has been approved in China for the 1st-line treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) whose tumours have exon 19 deletions or exon 21 (L858R) mutations.
6 hours ago · The Hong Kong government’s decision in 2021 to give up 7.5 million doses of AstraZeneca’s Covid-19 vaccines was triggered by safety concerns, a pandemic adviser has revealed in his newly ...
Aug 9, 2023 · AstraZeneca has signed a deal with Chinese pharmaceutical company CanSino Biologics to develop potential messenger RNA vaccines, as the Anglo Swedish company expands its work to include the...
Mar 23, 2023 · AstraZeneca’s Calquence (acalabrutinib), a next generation, selective Bruton’s tyrosine kinase (BTK) inhibitor, has been conditionally approved in China for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
